SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Pfizer Oral COVID-19 Drug, Paxlovid, Added to Formulary
Date: January 5, 2022
Attention: All Providers
Effective Date: December 27, 2021Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Health and Human Services Commission (HHSC) added Paxlovid to the Medicaid and Children’s Health Insurance Program (CHIP) formulary as a payable pharmacy benefit on December 27, 2021. The medication treats mild-to-moderate COVID-19 in adults and children 12 years of age and older, who are at high risk for progression to severe COVID-19.
HHSC added the following national drug codes (NDC) for Paxlovid:
Drug name
Dosage
Package size
NDC
Paxlovid EUA
300-100mg
6 tablets
00069-1085-06
Paxlovid EUA
300-100mg
30 tablets
00069-1085-30
Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300mg of nirmatrelvir (two 150mg tablets) with 100mg of ritonavir (one 100mg tablet), with all three tablets taken together orally twice daily for 5 days.
How this impacts providers: Paxlovid requires a prescription and should be initiated after diagnosis of COVID-19 within 5 days of symptom onset. This medication is not authorized for the prevention of COVID-19. Providers can find more information at the DSHS Therapeutics website, which includes a map of pharmacies where DSHS has distributed Paxlovid for the week of December 27, 2021, and an update on the recently authorized therapeutics for COVID-19. DSHS will revise the site when they distribute additional allocations of Paxlovid in the coming weeks.
Next steps for providers: Providers should share this update with their staff.
If you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org
